



This Trading Floor Research report contains:

Technology Sector Update

Editas Medicine (EDIT)

Direxion Financial Bear 3x (FAZ)

Technology Sector Update

Friday's rally did not improve accumulation levels in the **communication services, real estate, financial services, consumer cyclicals, industrials,** and **energy sectors**, all of which have recently issued sell signals.

The **technology sector**, however, led Friday's rally and closed above a significant Fibonacci 1.618 level, which had previously halted progress for 14 sessions. This move could generate additional enthusiasm in the sector and potentially elevate market levels.

Unfortunately, the rally in technology occurred on below-average volume, amid rising distribution levels, each time it attempted to break through the critical 1.618 level. This suggests a lack of conviction, as the technology sector's accumulation continues to decline, approaching 100-day lows. Consequently, while the weekly close was successful in terms of price, it did little to improve overall demand.

Solar stocks were the main drivers of the technology sector's upward move on Thursday and Friday, significantly contributing to the sector's ability to close above the strong Fibonacci 1.618 level. On Friday, the solar industry group led the market higher, gaining 5.11%.

I remain particularly focused on the solar group and continue to hold my position in **TOYO (TOYO)**. After selling half of my remaining position at the 8.45 Fibonacci target for a 53.6% gain, TOYO has since pulled back to its third Fibonacci target at 7.22, which also represents a breakout level from its primary IPO base. Once I receive new confirmation at this level, I will likely repurchase my entire position.

Among the technology leaders from Friday, the solar sector shows significant accumulation and may possess enough strength to continue pushing the tech sector higher. Other emerging solar stock leaders are in the process of setting up, and confirmation of their move higher is likely to come soon.

Technology Sector



Solar Energy Industry Group 260.00 252.01 240.00 228.75 218.00 220.00 261.8 (218.00) 210.49 202.75 200.00 181.28 180.00 161.8 (181.28) 167.76 125.0 (167.76) 158.58 112.6 (163.19) 160.00 140.21 140.00 **Massive** 120.00 accumulation confirms the move higher May Jul Oct Jun Aug 10/24/2025 Arith X Up/Down Volume Ratio ▼ Donchian Channels 100 ▼ Donchian Channels 20 ▼ 1.79 0.50




Confirmed Buy: Editas Medicine (EDIT)

- Sector and Industry Group: Healthcare/Biotechnology. The healthcare sector issued a new buy signal on October 1 after experiencing a surge from a one-year base. While most sectors have issued sell signals, the healthcare sector continues to show strong price and volume momentum. On Monday, I purchased shares of Editas Medicine (EDIT), a rising leader in the gene-editing segment of healthcare biotechnology. This subgroup currently has the highest concentration of emerging leaders within the healthcare sector. Other strong contenders include Caribou Biosciences (CRBU) and CRISPR Therapeutics (CRSP), for which I am also waiting for confirmation. The powerful accumulation in the gene editing group suggests it could lead the healthcare sector in its next upward move.
- Editas Medicine (EDIT) is a clinical-stage biopharmaceutical company that develops gene editing medicines using a proprietary platform based on CRISPR technology.
- Editas Medicine's (EDIT) accumulation is exceeding levels that previously drove the stock higher in February, where it saw a five-day gain of 185%. However, those gains occurred under the weekly cloud, which limited upward potential. Monday's move has positioned EDIT above the weekly cloud for the first time since September 2021, removing significant overhead resistance. Additionally, closing above the weekly cloud often triggers a substantial move. This breakout aligns with EDIT completing an ascending base that began in February. Furthermore, an ascending triple-top breakout on the point-and-figure chart highlights strong demand for EDIT shares.
- Position Started at 1-star.
- Editas Medicine (EDIT) was purchased at 4.08.
- Editas Medicine (EDIT) is undergoing significant accumulation with an Up/Down Volume Ratio at 1.70, after hitting 52-week highs.
- Editas Medicine (EDIT) closed at 3.76.
- Editas Medicine (EDIT) has an anchored VWAP of 17.82.
- •The Fibonacci sell targets: 1st target 4.54; 2nd target 4.74; 3rd target is 5.04; 4th target is 5.99.
- Stop price: Close below 1.56.

Editas Medicine (EDIT)






Confirmed Buy: Direxion Financial Bear 3x (FAZ)

- Position: Short the Financial Sector. This trade is designed to move 3x the inverse daily performance of the Financial Sector.
- The Direxion Financial Bear 3x (FAZ) trade is designed to take advantage of the next potential move lower in the financial services sector.
- After a six-session retracement, the **financial services sector** concluded the week at 50% of its recent decline. The volume-weighted average price (VWAP) and the ascending trendline from the September 23 peak also halted the upward movement on Friday. Holding at the strong 50% Fibonacci level indicates that the bears are in control. A confluence of technical resistance suggests a downward move may resume quickly. Since the sell signal on October 10, the chart has shown increasingly bearish signs, with accumulation reaching 100-day lows. To capitalize on a potential further decline, I purchased the **Direxion Financial Bear 3x ETF (FAZ)** on Wednesday.
- The position was purchased at 43.55 and started at 1-star(*).
- Direxion Financial Bear 3x (FAZ) closed at 42.20.
- Direxion Financial Bear 3x (FAZ) is undergoing significant accumulation, with accumulation approaching 100-day highs.
- The Fibonacci sell targets: 1st target 46.02; 2nd target 46.99; 3rd target is 48.41; 4th target is 52.27.
- Stop sell price: Close below 42.16.

Direxion Financial Bear 3x (FAZ)



Direxion Financial Bear 3x (FAZ)



Financial Sector




Disclaimer

Before using this site, please make sure that you note the following important information:

Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended only for the recipient specified in the message. It is strictly forbidden to share any part of this message with any third party without the written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion so that we can ensure such a mistake does not occur in the future.



The results do not represent the performance of all selections made by the Trading Floor Research (TFR) newsletter.

We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only, and nothing herein constitutes investment, legal, accounting, or tax advice or a recommendation to buy, sell, or hold a security. No recommendation or advice is given on whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors, or markets identified and described were or will be profitable. All information is current as of the date herein and is subject to change without notice.